Century Therapeutics (IPSC) Enterprise Value (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Enterprise Value of -$134.8 million for Q1 2026, up 18.36% year-over-year from -$113.9 million in Q1 2025, and up 20.02% quarter-over-quarter from -$168.6 million in Q4 2025.
Century Therapeutics (IPSC) Enterprise Value (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Enterprise Value for 7 consecutive years, with -$134.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 18.36% year-over-year to -$134.8 million; the TTM figure through Mar 2026 stood at -$134.8 million (up 18.36% YoY), while the FY2025 annual figure was -$168.6 million, up 10.96% from the prior year.
- Enterprise Value climbed to -$134.8 million in Q1 2026 per IPSC's latest filing, from -$168.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$132.7 million in Q3 2025 and bottomed at -$378.8 million in Q2 2022.
- Historically, Enterprise Value has averaged -$217.3 million across 5 years, with a median of -$189.3 million in 2024.
- Annual changes were most pronounced in 2022 — Enterprise Value tumbled 41.56% — and 2023, when it surged 58.71%.
- Century Therapeutics' Enterprise Value stood at -$315.5 million in 2022, then soared by 45.25% to -$172.7 million in 2023, then declined by 9.58% to -$189.3 million in 2024, then rose by 10.96% to -$168.6 million in 2025, then grew by 20.02% to -$134.8 million in 2026.
- Business Quant data shows IPSC's Enterprise Value at -$134.8 million in Q1 2026, -$168.6 million in Q4 2025, and -$132.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | -260.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -260.08 Mn |
| Mar 31, 2026 | -134.80 Mn |
| Dec 31, 2025 | -168.55 Mn |
| Sep 30, 2025 | -132.75 Mn |
| Jun 30, 2025 | -155.84 Mn |
| Mar 31, 2025 | -165.12 Mn |
| Dec 31, 2024 | -189.29 Mn |
| Sep 30, 2024 | -198.11 Mn |
| Jun 30, 2024 | -196.40 Mn |
| Mar 31, 2024 | -192.02 Mn |
| Dec 31, 2023 | -172.74 Mn |
| Sep 30, 2023 | -169.51 Mn |
| Jun 30, 2023 | -156.40 Mn |
| Mar 31, 2023 | -251.47 Mn |
| Dec 31, 2022 | -315.50 Mn |
| Sep 30, 2022 | -355.86 Mn |
| Jun 30, 2022 | -378.76 Mn |
| Mar 31, 2022 | -361.02 Mn |
| Dec 31, 2021 | -222.88 Mn |
| Sep 30, 2021 | -295.15 Mn |